PAB
Patrys Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-14.76%
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Patrys Ltd. engages in the commercialization of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. The company has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.
📈 Performance
Price History
-71.31%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.01
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PAB
2
📊 Total Capital Earnings
$232.01
🔃 Average investment frequency
2 days
💵 Average investment amount
$214
⏰ Last time a customer invested in PAB
1079 days
PAB investor breakdown
💵 Income of investors
More than 200k
150k - 200k
50%
100k - 150k
50k - 100k
50%
Less than 50k
👶 Age of investors
18 - 25
26 - 34
50%
35 - 90
50%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in PAB also invest in...
Archer Materials Ltd. is a materials technology company, which engages in the developing advanced semiconductor devices and processor chips related to quantum computing and medical diagnostics in Australia. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-08-14. The company is engaged in developing advanced semiconductor devices, including chips relevant to quantum computing and medical diagnostics. Its principal activities include technology development, including its quantum computing qubit processor chip (12CQ chip) and lab-on-a-chip biochip technology and utilizing semiconductor technology development infrastructure and facilities, research, and development to support research activities. The company focuses on advancing quantum computing and miniaturizing medical labs onto a chip. The company designs and integrates materials for operating qubits in quantum technologies and building graphene transistors for enhanced biosensing. Its development spans qubit processors for practical quantum computing technology, and lab-on-a-chip biosensors for integrated bioelectronics. The company develops its biochip for digitizing biologically relevant signals like those from viruses.
🙌 Performance (5Yr p.a)
13.85%
📊 Share price
$0.22 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
12.27%
📊 Share price
$126.64 AUD
🌏 GLOBAL
🤖 TECHNOLOGY
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
FAIR.AX was created on 2017-11-27 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes Australian companies that have passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
3.30%
📊 Share price
$20.90 AUD
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
💸 FINANCIALS
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.24%
📊 Share price
$138.29 AUD
💸 FINANCIALS
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
🙌 Performance (5Yr p.a)
12.98%
📊 Share price
$14.81 AUD
🇦🇺 EX AUSTRALIA
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
Want more shares? Try these...
Pacific Current Group Ltd. engages in the business of investing in asset managers, private advisory, placement, and investment related firms. The company is headquartered in Sydney, New South Wales and currently employs 20 full-time employees. The firm is engaged in investing in asset managers, private advisory, placement and investment-related firms on a global basis. The firm operates a portfolio of 15 specialist boutiques in Australia, India, Luxembourg, the United States, and the United Kingdom. The Company’s portfolio represents an array of strategies, diversified across investment strategy, geography, revenue model, and client type. Its portfolio of companies includes Aether Investment Partners, LLC, Astarte Capital Partners, LLP, Carlisle Management Company, S.C.A., Cordillera Investment Partners, LP, Victory Park Capital Advisors, LLC and others. Aether Investment Partners, LLC is focused on private investments in natural resources, infrastructure and opportunistic real assets. Astarte Capital Partners, LLP is focused on infrastructure, natural resources, transportation, and real estate.
🙌 Performance (5Yr p.a)
13.70%
📊 Share price
$10.85 AUD
💰 HIGH DIVIDEND
📈 HIGH PRICE GROWTH
💸 FINANCIALS
Platinum Asia Investments Ltd is a AU-based company operating in industry. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-09-21. Platinum Asia Investments Limited is an Australia-based investment company. The firm's investment objective is to provide capital growth over the long term through investing primarily in undervalued listed securities of companies in the Asian region (ex-Japan) across sectors. The company offers investors an easy and convenient means of accessing an actively managed, diversified portfolio of Asian (ex-Japan) companies across industry sectors, providing exposure to undervalued businesses that are benefiting from Asia’s dynamic growth and transformation. The company aims to achieve net returns over a five-year plus investment horizon that are in excess of the benchmark (MSCI All Country Asia ex Japan Net Index (A$)) returns. The company invests in sectors that include consumer discretionary, industrials, information technology, real estate, financials, materials, consumer staples, communication services, health care, energy and others. The Company’s investment manager is Platinum Investment Management Limited.
🙌 Performance (5Yr p.a)
0.07%
📊 Share price
$0.93 AUD
💰 HIGH DIVIDEND
PharmAust Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2001-10-05. The Company’s segments include Corporate and Research. The firm is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The firm's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The firm is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. The company is focused on starting Phase II/III clinical study of MPL. The company has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. The company is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.
🙌 Performance (5Yr p.a)
3.45%
📊 Share price
$0.17 AUD
📦 LOGISTICS
